APOE and BDNF polymorphisms moderate amyloid β-related cognitive decline in preclinical Alzheimer’s disease
Authors/Creators
Y Y. Lim
V L. Villemagne
Simon Laws, Edith Cowan University
R H. Pietrzak, Yale University School of Medicine
P J. Snyder
D Ames
K A. Ellis
K Harrington
A Rembach
Ralph N. Martins, Edith Cowan University
C C. Rowe
C L. Masters, University of Melbourne
P Maruff
Abstract
Accumulation of β-amyloid (Aβ) in the brain is associated with memory decline in healthy individuals as a prelude to Alzheimer’s disease (AD). Genetic factors may moderate this decline. We examined the role of apolipoprotein E (ε4 carrier[ε4+], ε4 non-carrier[ε4−]) and brain-derived neurotrophic factor (BDNFVal/Val, BDNFMet) in the extent to which they moderate Aβ-related memory decline. Healthy adults (n=333, Mage=70 years) enrolled in the Australian Imaging, Biomarkers and Lifestyle study underwent Aβ neuroimaging. Neuropsychological assessments were conducted at baseline, 18-, 36- and 54-month follow-ups. Aβ positron emission tomography neuroimaging was used to classify participants as Aβ− or Aβ+. Relative to Aβ−ε4−, Aβ+ε4+ individuals showed significantly faster rates of cognitive decline over 54 months across all domains (d=0.40–1.22), while Aβ+ε4− individuals showed significantly faster decline only on verbal episodic memory (EM). There were no differences in rates of cognitive change between Aβ−ε4− and Aβ−ε4+ groups. Among Aβ+ individuals, ε4+/BDNFMet participants showed a significantly faster rate of decline on verbal and visual EM, and language over 54 months compared with ε4−/BDNFVal/Val participants (d=0.90–1.02). At least two genetic loci affect the rate of Aβ-related cognitive decline. Aβ+ε4+/BDNFMet individuals can expect to show clinically significant memory impairment after 3 years, whereas Aβ+ε4+/BDNFVal/Val individuals can expect a similar degree of impairment after 10 years. Little decline over 54 months was observed in the Aβ− and Aβ+ ε4− groups, irrespective of BDNF status. These data raise important prognostic issues in managing preclinical AD, and should be considered in designing secondary preventative clinical trials.
Document Type
Journal Article
Date of Publication
1-1-2015
Faculty
Faculty of Health, Engineering and Science
Publisher
Nature Publishing Group
School
School of Medical Sciences
RAS ID
18819
Copyright
free_to_read
Comments
Lim, Y., Villemagne, V., Laws, S. , Pietrzak, R., Snyder, P., Ames, D., Ellis, K., Harrington, K., Rembach, A., Martins, R. N., Rowe, C., Masters, C., & Maruff, P. (2015). APOE and BDNF polymorphisms moderate amyloid β-related cognitive decline in preclinical Alzheimer’s disease. Molecular Psychiatry, 20, 1322–1328. https://doi.org/10.1038/mp.2014.123